Rockwell Medical (NASDAQ:RMTI) Raised to “Strong-Buy” at RODMAN&RENSHAW

Rockwell Medical (NASDAQ:RMTI) was upgraded by research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Several other equities research analysts have also issued reports on RMTI. Rodman & Renshaw initiated coverage on shares of Rockwell Medical in a research note on Thursday. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Rockwell Medical in a research report on Wednesday, September 11th. Finally, StockNews.com upgraded Rockwell Medical from a “hold” rating to a “buy” rating in a research report on Wednesday.

Rockwell Medical Trading Down 5.4 %

NASDAQ RMTI opened at $2.36 on Thursday. The stock’s 50-day moving average is $3.70 and its 200-day moving average is $2.60. The firm has a market cap of $76.11 million, a P/E ratio of -47.20 and a beta of 1.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.60. Rockwell Medical has a one year low of $1.16 and a one year high of $5.15.

Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Tuesday, November 12th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The company had revenue of $28.32 million for the quarter, compared to analysts’ expectations of $25.99 million. Rockwell Medical had a negative net margin of 1.25% and a positive return on equity of 8.55%. Sell-side analysts anticipate that Rockwell Medical will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Rockwell Medical

Large investors have recently bought and sold shares of the business. Concurrent Investment Advisors LLC acquired a new position in shares of Rockwell Medical during the third quarter worth $40,000. Verus Capital Partners LLC acquired a new stake in shares of Rockwell Medical during the 3rd quarter valued at approximately $51,000. Barclays PLC acquired a new stake in Rockwell Medical in the 3rd quarter valued at about $90,000. Beacon Financial Advisory LLC purchased a new position in Rockwell Medical during the third quarter worth $98,000. Finally, XTX Topco Ltd raised its position in shares of Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after buying an additional 8,922 shares during the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.